E-Therapeutics PLC
LSE:ETX

Watchlist Manager
E-Therapeutics PLC Logo
E-Therapeutics PLC
LSE:ETX
Watchlist
Price: 9 GBX -6.74% Market Closed
Market Cap: 52.6m GBX

E-Therapeutics PLC
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

E-Therapeutics PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
E-Therapeutics PLC
LSE:ETX
Operating Income
-ÂŁ10.2m
CAGR 3-Years
-52%
CAGR 5-Years
-9%
CAGR 10-Years
-7%
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Operating Income
-$201.1m
CAGR 3-Years
-9%
CAGR 5-Years
-109%
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Operating Income
-$273.9m
CAGR 3-Years
-15%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Operating Income
-ÂŁ70.5m
CAGR 3-Years
18%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Operating Income
ÂŁ68.6m
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
6%
Oxford BioMedica PLC
LSE:OXB
Operating Income
-ÂŁ30.7m
CAGR 3-Years
-20%
CAGR 5-Years
-19%
CAGR 10-Years
-9%
No Stocks Found

E-Therapeutics PLC
Glance View

Market Cap
52.4m GBX
Industry
Biotechnology

e-Therapeutics Plc is a drug discovery and development company, which engages in the provision of evaluation services to investors and pharmaceutical companies. The company is headquartered in Witney, Oxfordshire and currently employs 18 full-time employees. The company went IPO on 2007-11-28. The firm's platform is a combination of databases and a suite of computational tools that employ network analysis, data mining, machine learning, artificial intelligence (Al) and optimization. Its in silico platform serves as a laboratory, which enables it to computationally test potential therapeutic interventions. Its network-driven drug discovery (NDD) technology performs computational phenotypic screens to identify efficacious drugs. Its genome-associated interactions networks (GAINs) technology interprets genomic data in the context of the biological networks, in which the genes function. Its ribonucleic acid (RNA) Interference, (RNAi) platform is in development to complement its computational toolset. The firm identifies new therapeutic approaches to modulate a specific mechanism involved in Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic indications through Galapagos NV (Galapagos).

ETX Intrinsic Value
Not Available

See Also

What is E-Therapeutics PLC's Operating Income?
Operating Income
-10.2m GBP

Based on the financial report for Jan 31, 2023, E-Therapeutics PLC's Operating Income amounts to -10.2m GBP.

What is E-Therapeutics PLC's Operating Income growth rate?
Operating Income CAGR 10Y
-7%

Over the last year, the Operating Income growth was -7%. The average annual Operating Income growth rates for E-Therapeutics PLC have been -52% over the past three years , -9% over the past five years , and -7% over the past ten years .

Back to Top